CADTH's Updated Recommendations present Provincial/Territorial Advocacy Opportunities:
You may recall that in February of this year, CADTH decided to review their recommendations on the four curative HCV medicines that are currently approved in Canada. This resulted in an updated recommendation for use on patients F0 and up, rather than F2 or higher - ie, fibrosis levels should not be an eligibility factor for treatment. (BTW, this is in line with AHC's Position paper released last November.)
As a follow up, our Policy Analyst Claire has been preparing some letters to the provinces and territories, letting them know about the update and congratulating them if their formularies are in line with the recommendations and if they are not, urging them to get in line.
Claire has also recently learned that the CDEC (Canadian Drug Expert Committee) will be releasing THEIR updated recommendations any day now, so we are waiting to see what they say, whether they further support CADTH's recommendations, which would strengthen those letters to the P/Ts significantly.
In the Yukon, Patricia worked with NDP MLA Jan Stick, who asked the Minister of Health during Question Period last week, why the F2 restriction is still in place even though the recommendation is that treatment be available for everyone infected.
If you would like support in helping to prep a friendly MPP or MLA to ask this question in your province, let us know, we would be happy to help.